Business
Financial and Strategic Review, Annual General Meeting, and Trading Halt
Ghent, Belgium, April 28, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE | REGULATED INFORMATION - INSIDE INFORMATION28 April 2026, 10:00 pm CEST Ghent, Belgium, 28 April 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces that it is conducting a review of a range of financial and strategic options to address its current financial position and the
About this update from Sequana Medical N.v
[{"type":"image","alt":"Sequana Medical NV","displaySize":"","headline":null,"caption":"Sequana Medical NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":64,"url":"https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZrIpOehiKz_M4rbjFpbY5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkw/https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960","width":300,"height":64}},"lazy":false},{"type":"text","content":"Ghent, Belgium, April 28, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE | REGULATED INFORMATION - INSIDE INFORMATION28 April 2026, 10:00 pm CEST","length":138,"tagName":"p"},{"type":"text","content":"Ghent, Belgium, 28 April 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces that it is conducting a review of a range of financial and strategic options to address its current financial position and the future of its business.","length":406,"tagName":"p"},{"type":"text","content":"This review is being undertaken with the assistance of the Company's advisers and may include, among other things, financing transactions, a strategic or corporate transaction (involving the Company or its assets), or other measures. At this stage, several options are being reviewed, but no decision has been taken, and there can be no assurance as to whether any final option will be available or whether any measures will be implemented, nor as to their outcome or timing.","length":479,"tagName":"p"},{"type":"text","content":"Annual general shareholders' meeting","length":40,"tagName":"p"},{"type":"text","content":"In accordance with its articles of association, the Company will convene its annual general shareholders' meeting to be held on 28 May 2026. Against the background of the ongoing review, however, the Company's statutory and consolidated financial statements for the financial year ended 31 December 2025, together with the related reports of the board of directors and the statutory auditor, are not yet available. The board of directors therefore intends, during that meeting, to adjourn the consideration of the agenda items relating to, inter alia, the review ...